Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03713983
Other study ID # TAPE 2018
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 23, 2018
Est. completion date December 31, 2029

Study information

Verified date April 2024
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study follows up patients who receive standard treatment for prescription narcotic drug use disorder, including opioids, benzodiazepines, and benzodiazepine-like drugs (z-drugs), at a specialized addiction service. The overall goal is to evaluate the proportion of patients who reduce or cease using prescription narcotics and the factors associated with treatment outcomes. No new treatments will be tested. Instead, the results will be used as the basis for a future randomized controlled trial to optimize treatment for narcotic drug use disorder.


Description:

Background: The study covers prescription narcotics and focuses on opioids and benzodiazepines (and related compounds). The use of opioids and benzodiazepines is relatively safe in the short term. However, long-term use for anxiety and chronic non cancer pain has limited scientific support. Moreover, use of opioids and benzodiazepines has been associated with a variety of adverse effects and both opioids and benzodiazepines are highly addictive. Clinical guidelines advise that narcotic analgesics and sedatives should not be used as first-choice treatments for pain, anxiety, or insomnia. Instead, guidelines recommend psychotherapy, physiotherapy, and non-narcotic pharmacological drugs (such as non-steroidal anti-inflammatory drugs and antidepressants), alternatives that are less addictive and more beneficial over time. Despite such recommendations, benzodiazepines and opioids are commonly prescribed and used over the long term. For patients who seek treatment for narcotic drug use disorder, tapering by gradual dose reduction is an important component but its effect is not well studied. Aims: This study aims to investigate the clinical trajectory and treatment outcome among patients with narcotic drug use disorder at specialized addiction treatment services. Specific aims: 1) The outcome of tapering of narcotic drugs at 6, 12, and 24 months follow-up 2) How the treatments provided (e.g., tapering; tapering plus psychological treatment) are associated with patient outcomes 3) How psychiatric symptoms and comorbidity are associated with patient outcomes 4) Predictors of narcotic drug abstinence and retention in treatment 5) The validity of psychiatric diagnoses in relation to drug use (i.e., whether the diagnosis changes significantly following drug detoxification) Methods: This is a naturalistic, prospective study of outcomes following treatment at a specialized service for prescription narcotic drug use disorder. Standardized screening and assessment tools will be used to investigate patients at baseline, evaluate the treatment patients receive over a 24-month period, and evaluate patient outcomes. All patients starting a new treatment period at the center will be invited to participate at the first visit to the clinic or as soon as possible thereafter. Written informed consent will be obtained. The study will conform to Good Clinical Practice (ICH-GCP) and the principles outlined in the Declaration of Helsinki. Measurements in the study include: urine drug screening, blood chemistry including screening for alcohol biomarkers, Drug Use Disorders Identification Test, Alcohol Use Disorders Identification Test, Patient Health Questionnaire, EuroQol -5D, Clinical Global Impressions Scale, Adult ADHD Self-Rating Scale - Screening, The Mini International Neuropsychiatric Interview, Version 7, the Life Events Checklist, the Insomnia Severity Index, the Benzodiazepine Withdrawal Symptom Questionnaire, the Subjective Opioid Withdrawal Scale, Generalized Anxiety Disorder - 7, Numeric Rating Scale for Pain, PROMIS Pain Interference - Short Form 4a, patient satisfaction, Substance use questionnaire, and Structural Clinical Interview for DSM-IV Axis II Personality Disorders Screening. Information regarding treatment at the unit (e.g. number and type of visits, somatic or psychiatric diagnoses) will be collected from medical records using the ICD codes. Diagnostic assessment will be performed according to both ICD-10 and DSM-5. The protocol allows for a 10-year follow-up using national registries. Study procedures and data collection will be regularly monitored by an external quality assurance organization. Analyses will be conducted using statistical software; p values < 0.05 will be considered significant. Prescription drug use, retention in treatment and the percentage of participants with negative urine samples and self-reported abstinence will be calculated at follow-ups. Regression analyses will be computed to assess factors associated with the outcome of tapering. To find a 95 % confidence interval around the point estimate (drug abstinence) with a margin of error not exceeding +/- 5 percentage points, where the assumed proportion is 0.3, at least 322 patients must be included. Alternatively, to find a 95 % confidence interval with a margin of error not exceeding +/- 10 percentage points, at least 81 patients must be included. A minimum of 81 patients will be included in the study. The study will include an analysis of dropout.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 400
Est. completion date December 31, 2029
Est. primary completion date December 31, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients seeking treatment for prescription narcotic drug use disorder (ICD-10: F111, F112, F131, and F132) - = 18 years - Willing to participate and who have provided written informed consent. Exclusion Criteria: - Inability to understand spoken and written study information. - Having started tapering prior to the start of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational study
Observational study

Locations

Country Name City State
Sweden Stockholm Centre for Dependency Disorders (www.beroendecentrum.se) Stockholm

Sponsors (2)

Lead Sponsor Collaborator
Johan Franck Public Health Agency of Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Diagnoses of substance use disorder(s) Number of participants with diagnoses of substance use disorder according to ICD-10 6-, 12-, and 24-month follow-up
Other Self-reported substance use self-reported data using standard question in ASI 6-, 12-, and 24 month follow-up
Other Psychiatric comorbidity Number of participants with psychiatric diagnoses according to ICD-10 6-, 12-, and 24-month follow-up
Other Personality traits SCID-2 Structured Clinical Interview for DSM-IV-Axis 2 Disorders, screening 6-, 12-, and 24-month follow-ups
Other Insomnia Insomnia Severity Index (ISI) 6-, 12-, and 24-month follow-up
Other Pain Scale The PROMIS pain interference - Short form 4a (PROMIS-PI SF 4a), is a four-item questionnaire measuring the extent pain interferes with functioning in daily life. Items are rated on a five-point scale ranging from "not at all" to "very much". Summed scores range from 4-20, higher scores indicating greater pain interference. The scale is recommended by the National Institute of Drug Abuse (NIDA). 6-, 12-, and 24-month follow-up
Other Quality of life, including self-rated health Measured by EuroQol 5D (EQ-5D), a two-part health index. Part one covers self-rated problems in five domains: mobility, self-care, everyday activities, pain/discomfort, and anxiety/depression. Each domain is rated on a five-level scale that indicates no problems to extreme problems. Part two consist of a visual analog scale (EQ-5D VAS); respondents assess their subjective health status on a 0 to 100 scale, where 0 is "the worst health you can image" and 100 "the best health you can imagine." 6-, 12-, and 24-month follow-up
Other Somatic health Number of participants with somatic diagnoses according to ICD-10 6-, 12-, and 24-month follow-up
Other Withdrawal symptoms Opioids Measured by the Subjective Opiate Withdrawal Scale (SOWS). The scale measures 16 common symptoms of opiate withdrawal. Symptoms are rated on a scale between 0 and 4, from "not at all" to "extremely." Higher scores indicating more withdrawal symptoms. 6-, 12-, and 24-month follow-up
Other Substitution treatment with opioids Prescription registry data 6-, 12-, and 24-month follow-up
Other Withdrawal symptoms Benzodiazepines The Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) 6-, 12-, and 24-month follow-up
Other Self-reported patient satisfaction with treatment Self-report data using standard question in the National Patient Survey (Sweden). Items measures patients' experience and satisfaction with care. Items are rated on a scale between 1 ("Not at all") and 5 ("Totally agree"), with the possibility to answer "Not applicable". 6-, 12-, and 24-month follow-up
Primary Change in prescription narcotic drug use Change in dosage of prescription narcotic drugs 6-, 12- and 24-month follow-up or at last visit; 10-year follow-up.
Secondary Prescription narcotic drug abstinence Measured by drug testing and self-reported substance use 6-, 12- and 24-month follow-up or at last visit
Secondary Retention in treatment Data collected from scheduled visit 6-, 12- and 24-month follow-up or at last visit
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT01413529 - HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users Phase 2
Completed NCT01141920 - Comparison of Two Counseling Induction Strategies N/A
Completed NCT00237822 - Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders Phase 2
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Active, not recruiting NCT02601495 - Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery
Recruiting NCT05534568 - The Oklahoma Parent-Child Assistance Program N/A
Completed NCT04907045 - An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care N/A
Completed NCT04268173 - Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3 Phase 3
Not yet recruiting NCT06317987 - Addressing Barriers to Care for Substance Use Disorder Pilot Study N/A
Completed NCT03373240 - Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention N/A
Active, not recruiting NCT06249542 - Implementing Screening for Cannabis and Other Drug Use Disorders in Primary Care: Impact on Diagnosis and Treatment N/A
Completed NCT02450240 - Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders
Recruiting NCT03069118 - 90-Day Online Substance Use Program N/A
Active, not recruiting NCT05160233 - Digital Treatments for Opioids and Other Substance Use Disorders in Primary Care N/A
Completed NCT03451344 - A Electronic System to Improve Recovery Outcomes in Patients With Drug Use Disorder N/A
Completed NCT00798538 - Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Phase 4
Completed NCT03684252 - Reducing Self-stigma in Persons With HIV and Drug Use Disorders in Primary Health Care Settings N/A

External Links